History of Aventis Pharma Ltd.
1956
- The Comp. was incorporated as Hoechst Fedco Pharma Pvt. limited on 31st March. The word `Private' was deleted on 19th April, 1961 as the Company was deemed to be Public Limited Comp. under Section 41-A of the Act.
- The Comp. manufacture bulk drugs, drug intermediates, veterinary formulations & pesticides. They established with financial and technical collaboration of Farbwerke Hoechst AG [now Hoechst AGs], West Germany, which is one of largest chemical & pharmaceutical manufacturing groups in the world.
- Under the Licence & Technical Collaboration Agreement dated 11th July, made between Hoechst AG & the Company, the Comp. was inter alia granted the right to use the word `HOECHST' in its corporate name and the use of trade marks owned by Hoechst AG in India in respect of various pharmaceutical preparations which would be manufactured and marketed by Comp. in India on the terms & conditions mentioned in the said Agreement.
- 10,000 Pref. & 10,000 No. of Equity shares of Rs 100 each issued to promoters. 5000 Pref. & 9,867 No. of Equity shares as Rights in proportion to holdings.
1957
- The Comp. set up a manufacturing unit at Mulund, for production of basic drugs. In also manufactures intermediates including some of the latest discoveries in the Hoechst Group involving high technology and application of sophisticated modern manufacturing techniques. It also supplies basic drugs to other pharmaceutical companies in India as well as to Europe.
1961
- 28,133 No. of Equity shares issued as Rights.
1967
- 37,800 bonus equity shares issued, propn., 3:5. In June & August, 17,000 No. of Equity shares issued as Rights.
1969
- 57,222 Bonus equity shares issued in the proportion 49:100.
1974
- 1,64,990 Bonus equity shares issued in the proportion 94:100,
1979
- 1,70,256 Bonus equity shares issued in the proportion 1:2.
1982
- The Comp. set up a manufacturing unit at the Kandla Free Trade Zone to cater to the increasing export market for its products.
- 2,55,384 Bonus equity shares issued in the proportion 1:2.
1984
- The main objects of public issue was to achieve the voluntary dilution of Hoechst AG holding in the Comp. from 50% to 40% and also to provide the requirements of long term resources for capital expenditure to be incurred on Acc. of normal replacement and renovation of capital assets, continuous modernisation & upgradation programmes to achieve efficiency & use of lates techniques and methods of manufacture to impart high quality & sophistication to the product range.
- 1,19,538 No. of equity shares issued [Prem. of Rs 100 per shares] in July, of which 3,800 shares to business associates & 9,600 shares to employees including working directorss] were reserved for preferential allotment. The balance 1,78,138 shares offered for public subscription.
1986
- The Land & building water works, plant & machinery of Company were revalued as on 31st December.
- A new Comp. under the name Hoechst Nepal Pvt. Ltd., was incorporated as a subsidiary of Comp. in February in Nepal.
1987
- A new extension of Haemaccel plant at Mulund & a multi-purpose fine chemicals plant for bulk drugs at Ankleshwar went into commercial production.
- During the year, an industrial licence was obtained for the manufacture of Petoxifylline [TRENTALs], 2 tonnes of Ciclopiroxolamine [BATRAFENs], an antifungal drug & 5.30 lakhs TPA of diagnostic reagents at Ankleshwar.
1988
- Industrial licence was, received for manufacture of 2 lakh doses of purified chick embroy cell culture vaccine [Human rabies vaccines] known as RABIPUR.
- The Comp. obtained Central Government approval under the M.R.T.P. Act, 1969 to the establishment of new undertaking for producing, processing & selling hybrid & high - yielding varieties of seeds.
- The Comp. issued 2,30,000 - 14% secured redeemable non-convertible debentures of Rs 100 each on private placement basis. These are redeemable at a premium of Rs 5 per debenture on 1st February, 1996.
1989
- The Comp. re-entered the antifugual market with the introduction of 'BATRAFEN' which was an original research product of Company's collaborators Hoechst AG, West Germany.
- The Comp. introduced a new insecticide 'HOSTATHION'. 'FLAVOMYCIN', a modern performance promoter for poultry was launched during the year.
- The Pharma formulation plant was commissioned at Ankleshwar in October, liquid injectible automatic filling line was commissioned in Mulund in September.
1990
- New pharma products introduced were TARIVID [a modern oral antibacterials], AVIL retard [sustained release formulation for treatment of allergiess] & TABLON [a formulation containing Ibuprofen for the treatment of pains].
- In co-operation with Boots Pharmaceuticals Ltd., a new anti-arthritic drug `FLUROFEN' was introduced.
- A letter of intent were received for BARALGAN Ketone & fomulations, Glybenclamide & formulations, Hostathion technical & formulations, Fenbendazole substance & formulations & Ethion technical and formulations at the Company works in Ankleshwar. Industrial license was received for manufacture of LASIX retard besides receiving endorsement for manufacture of 13 tonnes of AVIL maleate.
1991
- A new herbicide Klass [Diurons] was introduced during the year. `Butox' & `Tolzan' were the new products introduced for external and internal parasites.
- Industrial licences were received for manufacture of Tonophosphan, Berenil & Fenbendazole & their formulations at Ankleshwar. Letters of intent were received for manufacture of Novalgin tablets and Roxatidine & their formulations at Ankleshwar & Lasiride and Betrafen & their formulations at Mulund.
- The Comp. revalued its free-hold land, buildings etc & the net surplus of Rs 470,733,868 arising out of its was transferred partly to capital reserve [Rs 149,489,737s] & to Revaluation reserve [Rs 321,244,131s].
1992
- A modern anti hypertensive `Rene Dil' & latest anti-ulcer drug. `Rotane' were introduced during the year.
- Industrial licences were received for manufacture of Baralgan, Glybenclamide, & their formulations, Roxatidine, Lasiride and formulations & Novalgin tablets at Ankleshwar & Batrafen formulations at Mulund.
- Letters of intent were received for manufacture of Ranipril and formulations, Tabalon tablets & Tarivid tablets at Ankleshwar and cosavil syrup & Streptase formulations at Mulund.
- An additional super centrifuge & auxilliary equipments for PCEC plant in Ankleshwar were installed & commissioned.
1993
- 19,38,411 No. of Equity shares of Rs 10 each issued at a premium of Rs 60 per share to Hoechst AG to raise its capital from 40% to 51%.
1994
- A product cardare, an ACE inhibitor was introduced. An oral typhoid vaccine called typhonal was also introduced. Candur-R, & antirabies vaccine was launched during the year.
- With effect from 1st April, the Scheme of Arrangement was sanctioned for transfer of company agrochemicals division to Hoechst Schering Agrofoo limited In terms of scheme every shareholder of the Company holding 50 shares, were allotted 10 shares of Rs 10 each of Hoechst Schering Agrofoo limited without any payment.
- Roussel India, limited in which the Comp. held 4,18,560 No. of equity shares out of 6,27,840 No. of equity shares of Rs 100 each issued is a subsidiary of Company.
- 115,15,311 shares issued at a bonus shares in proportion 1:1.
1995
- The new products such as ACE inhibitor, Cardace etc. was attributed. The Comp. launched INSUMAN [human insulins] apart from Floxidin a new broad spectrum antibiotic. Due to the technical difficulties, the Company had to close both foot & mouth disease vaccine & Candur DHL plants.
- Roussel India Ltd., the Company subsidiary was amalgamated with the Company. Accordingly the name of Comp. was changed to Hoechst Marion Roussel Ltd., effective 1st January, 1996.
1996
- `Insuman' an anti-diabetic drug was launched. The production of `Baralgan' was suspended as per the Govt. order.
- The capacity of Rabipur plant at Ankleshwar was expanded from 1.8 million doses to 3.5 million doses per annum to meet the increased demand for product.
- The Comp. proposed to set up a joint venture Comp. with Chiron Corporation, USA for manufacture of vaccines of Chiron group. The company proposed to take up 49% of share capital of said company.
1997
- The Comp. proposed to introduce four new products viz. Frisium [anti-epileptics]. Amaryl [oran anti-diabetics] cefrom [4th generation cephalosporins] & Targocil [Glycopeptides]
- The German drug multinational Hoechst Roussel is buying out the equity stakes of Colour Chem & two individual entrepreneurs in its Indian joint venture, Hoechst Roussel Vet Private Limited, to convert it into a fully-owned subsidiary.
- Currently, Hoechst Roussel Vet GmbH, along with its subsidiary Hoechst Schering Agrevo Ltd, holds 51 per cent equity in the joint venture.
- Hoechst-Huabei Pharmaceuticals Co. Ltd, is a 50:50 greenfield joint venture between Hoechst Marion Roussel & North china Pharmaceutical Group Corporation [NCPCs].
- Hoechst Marion Roussel recently forged a manufacturing joint venture for vaccines with the Chiron group in India.
1998
- Hoechst Marion Roussel [HMRs], a 51 per cent subsidiary of Hoechst Marion Roussel, Germany, has a significant presence in pharmaceutical and agrochemicals industries.
- The new joint venture Comp. will manufacture the anti rabies vaccine Rabipur & other vaccines of Chiron Group.
- HMRL had purchased the 33.33 per cent shareholding of Roussel Laboratories UK in Roussel India, to make the latter a 100 per cent subsidiary of HMRL.
- The Comp. is all set to transfer its animal healthcare business to a joint venture company, in which HMR will have a 49 per cent stake and Chiron Corporation of US 51 per cent.
- Hoechst proposes to enter into a joint venture with Chiron Corporation of USA for manufacture of vaccines.
1999
- Hoechst Marion Roussel has launched a voluntary retirement scheme [VRSs] at its Mulund factory in Mumbai.
2000
- The Comp. plans to introduce variants of brands like Allegra and Tavanic in the domestic market.
- The Comp. has re-designated Ramesh Subrahmanian as deputy managing director of Comp. with effect from 1st July.
- The Comp. & Rhone-Poulenc Rorer [Indias] limited two separate Indian subsidiaries of French Pharmaceuticals & Chemicals major, Aventis SA, are implementing employee stock option schemes as part of the parent company worldwide strategy.
- Hoechst Marion Roussel limited will acquire 29,55,608 No. of Equity shares of Rhone-Poulenc Rorer at Rs 15 per share.
- Hoechst Marion Roussel will now be known as Aventis Pharma even as it aims to maintain a leading position within the Indian pharma sector.
2002
-Aventis Pharma Ltd has informed that the Board of Directors of Comp. has, at its meeting held on October 30, 2002 appointed Mr W Wagner as a Director of Comp. in the casual vacancy caused by resignation of Mr J Silvestre.
-Bombay High Court sanctions amalgamation of Rhone-Poulenc Rorer with Aventis Pharma Ltd.
-Aventis Pharma increased its sales to Rs.261cr by 16% as against the corresponding period of previous year.
2003
-Aventis Pharma Ltd has filed a lawsuit against alleging patent infringement on Six Orange Book patent .
-CRISIL withdrew its AAA rating for Rs.30cr non-convertible Debenture issue of Aventis Pharma Ltd.
-Mr.M.G. Rao & Dr.S Bhattacharya have been appointed as Alternate Directors to Dr.Carlo de Notaristefani & Mr.W.W.Wagner.
-Aventis Pharma has appointed Mr.Ramesh Subramanian, MD as the Vice-president of the Respiratory Sales for North-East & Mid-Atlantic US.
2007
-Aventis Pharma Limited has appointed Mr. Eric Le-Bris as an Additional Director.
-Aventis Pharma Limited has appointed Mr. S.C. Ghoge as Alternate Director to Mr. Eric Le-Bris. Mr. Ghoge being an employee of Company, has been appointed a Wholetime Director'.
2008
-Mumbai: Aventis Pharma has launched insulin drug Lantus in a prefilled disposable pen called Solostar.
